| Literature DB >> 32205424 |
Frank M Davis1, Aaron denDekker1, Andrew Kimball2, Amrita D Joshi1, Mahmoud El Azzouny3, Sonya J Wolf1, Andrea T Obi1, Jay Lipinski4, Johann E Gudjonsson5, Xianying Xing5, Olesya Plazyo5, Christopher Audu1, William J Melvin1, Kanakadurga Singer6, Peter K Henke1, Bethany B Moore7,8, Charles Burant7, Steven L Kunkel4, Katherine A Gallagher9,8.
Abstract
Macrophages are critical for the initiation and resolution of the inflammatory phase of wound healing. In diabetes, macrophages display a prolonged inflammatory phenotype preventing tissue repair. TLRs, particularly TLR4, have been shown to regulate myeloid-mediated inflammation in wounds. We examined macrophages isolated from wounds of patients afflicted with diabetes and healthy controls as well as a murine diabetic model demonstrating dynamic expression of TLR4 results in altered metabolic pathways in diabetic macrophages. Further, using a myeloid-specific mixed-lineage leukemia 1 (MLL1) knockout (Mll1f/fLyz2Cre+ ), we determined that MLL1 drives Tlr4 expression in diabetic macrophages by regulating levels of histone H3 lysine 4 trimethylation on the Tlr4 promoter. Mechanistically, MLL1-mediated epigenetic alterations influence diabetic macrophage responsiveness to TLR4 stimulation and inhibit tissue repair. Pharmacological inhibition of the TLR4 pathway using a small molecule inhibitor (TAK-242) as well as genetic depletion of either Tlr4 (Tlr4-/- ) or myeloid-specific Tlr4 (Tlr4f/fLyz2Cre+) resulted in improved diabetic wound healing. These results define an important role for MLL1-mediated epigenetic regulation of TLR4 in pathologic diabetic wound repair and suggest a target for therapeutic manipulation.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32205424 PMCID: PMC7443363 DOI: 10.4049/jimmunol.1901263
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422